Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Outlook Therapeutics (OTLK) Long-Term Debt Issuances (2016 - 2017)

Outlook Therapeutics (OTLK) has disclosed Long-Term Debt Issuances for 3 consecutive years, with $5.0 million as the latest value for Q2 2017.

  • On a quarterly basis, Long-Term Debt Issuances rose 3067584.66% to $5.0 million in Q2 2017 year-over-year; TTM through Sep 2025 was $5.0 million, a N/A change, with the full-year FY2025 number at $33.1 million, changed N/A from a year prior.
  • Long-Term Debt Issuances was $5.0 million for Q2 2017 at Outlook Therapeutics, up from $1.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $8.4 million in Q4 2016 to a low of -$582795.0 in Q3 2016.
  • A 3-year average of $2.2 million and a median of $1.1 million in 2016 define the central range for Long-Term Debt Issuances.
  • Peak YoY movement for Long-Term Debt Issuances: tumbled 100.01% in 2016, then surged 3067584.66% in 2017.
  • Outlook Therapeutics' Long-Term Debt Issuances stood at $187388.0 in 2015, then soared by 4356.0% to $8.4 million in 2016, then plummeted by 40.12% to $5.0 million in 2017.
  • Per Business Quant, the three most recent readings for OTLK's Long-Term Debt Issuances are $5.0 million (Q2 2017), $1.6 million (Q1 2017), and $8.4 million (Q4 2016).